NEWSROOM
Stay current with MiRXES
Media Releases
10 August 2023
Mirxes announced today that its flagship product GASTROClearTM, a PCR-based in vitro diagnostic test for early detection of gastric (stomach) cancer, has been granted Breakthrough Device Designation by the U.S. Food and Drug Administration (FDA). Globally, this marks the first time that 1) a blood miRNA test, 2) an in vitro diagnostic (IVD) test for early detection of gastric cancer, and 3) a molecular in vitro diagnostic test developed in Southeast Asia, has received a Breakthrough Device Designation from the U.S. FDA.
25 July 2023
Mirxes announced today the successful completion of its Series D funding round, securing a total of US$50 million. In addition to securing the Series D funding, Mirxes is pleased to announce that it has filed the listing application with The Stock Exchange of Hong Kong Limited (HKEX) under Chapter 18A of the Rules Governing the Listing of Securities on HKEX.
29 November 2022
Media Coverage
Stay informed and keep abreast with our media news.
26 Jan 2023
20 Apr 2022
Collaborations
Our partnerships
15 Sep 2021
31 Aug 2021
Insights
Welcome to our knowledge base of insights in the frontiers of the biotech industry.
Across the many functional teams in MiRXES, from R&D to manufacturing and commercial, our women in science wear many different hats — to great success.
SOCIAL MEDIA
- Genomics
- Clinical Sequencing
- Research Sequencing
- Cancer Screening
- GASTROClear for Patients
- GASTROClear for Medical Professionals
- Cancer Treatment Selection
- APEX Tissue Panel for Medical Professionals
- Infectious Diseases
- Fortitude 2.1
- Fortitude 3.0
- Fortitude Syndromic Panel
- CoVClear Mutation Panel
- Swab & Saliva Collection
- RNA Extraction Kit & Instruments